COX-2 inhibitors in NSCLC: never-ending story or misplaced?

Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S191-S194. doi: 10.21037/tlcr.2018.04.17.

Authors

Alex Martinez-Marti¹, Alejandro Navarro¹, Enriqueta Felip¹

Affiliation

¹ Medical Oncology Department, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.

No abstract available

Publication types

Editorial
Comment